What happened with CALC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
CalciMedica concentrates most of its research effort and funding on Auxora, its lead experimental drug. For acute pancreatitis, it is developing Auxora to reduce inflammatory injury and organ dysfunction during an attack, rather than simply treat symptoms. It has no drug approved for sale and has never earned product-sales revenue.
Investors and lenders, rather than drug buyers, currently supply its funding. The company needs substantial additional capital to finish development and pursue commercialization. Future product sales depend on successful trials and regulatory approval; it cannot market its candidates in the United States without FDA approval. Insurance coverage and reimbursement would also affect sales if a drug reaches the market.
Auxora’s development has faced a safety setback: in January 2026, CalciMedica stopped dosing and enrollment in its KOURAGE trial for acute kidney injury with respiratory failure after a mortality imbalance prompted a monitoring committee’s recommendation. Follow-up and data collection continued. The company also relies on outside organizations to conduct trials and manufacture its drugs, and expects to outsource commercial production if a product is approved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
CalciMedica’s prospects hinge on Auxora’s clinical and regulatory progress, especially in acute pancreatitis, where Panafina and SCM Lifsciences are more directly relevant drug developers than the supplied candidates.
Fed Interest Rate Decision
CalciMedica’s interest-rate decision matters because it can affect the cost of its floating-rate loan and the cash left to fund clinical development.
Expected4.0%Last release4.0%
If it comes in above expectations
If policy rates rise more than expected, interest costs on CalciMedica’s $10 million loan may increase, leaving less cash for its clinical trials.
If it comes in below expectations
If policy rates fall more than expected, interest costs on CalciMedica’s $10 million loan may ease, leaving more cash available for clinical trials.
CalciMedica, Inc. earningsThis company
CalciMedica has no approved product or product-sales revenue, so this report will show how much cash clinical development is using and how far its funding can carry it toward key milestones.
Read operating cash outflow alongside cash, cash equivalents and short-term investments at quarter-end, then compare research and development spending with clinical progress. Slower cash use while development advances would show the funds can support more work; faster use without matching progress would shorten the runway and make financing, cutting programs or delaying trials more pressing.
